Loading
Life sciences · Journal article
Discover Nano · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The non-invasive skin cancer, especially that of the basal cell carcinoma and squamous cell carcinoma, is an increasing global health burden. Traditional methods of treatment, such as surgery, cryotherapy, and topical chemotherapeutics, are all limited by poor penetration into the skin, non-specific drug delivery, cosmetic destruction, and tumour reappearance. Moreover, the tumour microenvironment (TME) significantly contributes to disease progression through inflammation, angiogenesis, immunosuppression, and therapeutic resistance, underscoring the need for more advanced, targeted treatment methods. The purpose of this review is to critically analyse the applications of the ethosome-based drug delivery system in the precision targeting and reprogramming of the TME in the treatment of non-invasive skin cancer. Ethosomes have better skin permeability and local drug delivery than standard topical systems. They also facilitate easy access to a wide variety of therapeutic agents, allowing specific interactions with tumour tissue and other critical components of the TME, leading to better therapeutic effects with fewer off-target effects. The ethosome-based drug delivery system is an attractive non-invasive therapeutic platform for managing skin cancer by efficiently reprogramming the TME via transdermal delivery. Although they have preclinical evidence supporting their potential, they need additional clinical validation and regulatory standardisation to be successfully translated into clinical use.